Zepbound (generic name: tirzepatide) is a once-weekly injectable prescription medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. It is manufactured by Eli Lilly and Company.
How It Works
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first of its kind approved for weight management. According to the FDA-approved prescribing information, it activates both the GIP and GLP-1 receptors simultaneously. GLP-1 receptor activation slows gastric emptying (meaning food moves more slowly out of the stomach), reduces appetite signals in the brain, and promotes feelings of fullness. GIP receptor activation is believed to complement these effects by influencing fat tissue metabolism and further modulating appetite. Together, these two mechanisms reduce caloric intake and support sustained weight loss. Tirzepatide is structurally based on the native GIP hormone sequence and is administered subcutaneously once weekly.
Side Effects by Week
| Time Period | Common Side Effects | What Helps |
|---|---|---|
| Week 1–2 (Starting dose: 2.5 mg) |
Nausea, decreased appetite, mild injection-site reactions (redness, itching), fatigue, diarrhea | Eat smaller, bland meals; avoid high-fat or spicy foods; stay hydrated; rotate injection sites; inject at the same time each week |
| Week 3–4 (Still at 2.5 mg or transitioning to 5 mg) |
Nausea may persist or intensify at dose escalation; vomiting, constipation, abdominal discomfort, burping | Eat slowly; stop eating when full; avoid carbonated beverages; increase fiber and water intake gradually for constipation; contact prescriber if vomiting is severe |
| Month 2–3 (5 mg and escalating toward 10 mg) |
Gastrointestinal symptoms typically begin to lessen; some patients experience continued constipation, heartburn (GERD), or hair thinning (telogen effluvium related to caloric restriction) | Continue hydration and dietary adjustments; discuss fiber supplements or stool softeners with prescriber; hair thinning is generally temporary and nutrition-related per SURMOUNT-1 data |
| Long-term (Maintenance doses: 10 mg, 12.5 mg, or 15 mg) |
GI side effects reduce significantly for most patients; injection-site bruising; potential muscle mass loss alongside fat loss | Ensure adequate protein intake; resistance exercise is often discussed with healthcare providers; report any new or worsening symptoms promptly |
Most Common Side Effects
- Nausea: Reported in up to 31% of patients in the SURMOUNT-1 trial at the 15 mg dose; most frequently occurs during dose escalation periods.
- Diarrhea: Occurred in approximately 23% of patients receiving 15 mg tirzepatide in SURMOUNT-1; generally mild to moderate in severity.
- Vomiting: Reported in approximately 20% of patients at the 15 mg dose in SURMOUNT-1; most common during the first weeks of therapy.
- Constipation: Occurred in approximately 17% of patients in SURMOUNT-1; results from slowed gastric motility caused by the drug's mechanism.
- Abdominal pain: Reported in roughly 10% of patients in SURMOUNT-1; typically described as cramping or discomfort.
- Injection-site reactions: Including redness, bruising, itching, and swelling; listed in FDA prescribing information as common local adverse events.
- Decreased appetite: Expected pharmacological effect; reported by a large proportion of participants across all SURMOUNT trials.
- Fatigue: Reported during early treatment phases in SURMOUNT-1 trial data; generally transient.
- Dyspepsia (indigestion) and belching: Listed in the FDA-approved prescribing information as common adverse reactions.
- Hair loss: Reported in SURMOUNT-1 as alopecia; attributed primarily to rapid weight loss and caloric restriction (telogen effluvium) rather than a direct drug effect.
Serious Side Effects
- ⚠️ BOXED WARNING — Thyroid C-Cell Tumors: The FDA prescribing information for Zepbound carries a boxed warning stating that tirzepatide caused thyroid C-cell tumors in rodents; it is unknown whether this applies to humans. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- ⚠️ Pancreatitis: Acute pancreatitis, including fatal cases, has been reported with GLP-1 receptor agonists; FDA labeling advises discontinuing Zepbound if pancreatitis is suspected and not restarting if confirmed.
- ⚠️ Acute Gallbladder Disease: Cholelithiasis (gallstones) and cholecystitis have been reported; FDA labeling notes that substantial or rapid weight loss is a known risk factor for gallstone formation.
- ⚠️ Hypoglycemia (with concomitant insulin secretagogues or insulin): FDA prescribing information warns of serious hypoglycemia risk when Zepbound is used alongside insulin or sulfonylureas; dose reductions of those agents may be required.
- ⚠️ Acute Kidney Injury: Reported in post-marketing experience with GLP-1 receptor agonists; dehydration from GI side effects is a contributing factor per FDA labeling.
- ⚠️ Hypersensitivity Reactions: Serious reactions including anaphylaxis and angioedema have been reported; FDA labeling states patients experiencing such reactions should discontinue Zepbound and seek emergency care.
- ⚠️ Diabetic Retinopathy Complications: FDA labeling notes reports of worsening diabetic retinopathy in patients with type 2 diabetes treated with tirzepatide; monitoring is recommended for patients with this history.
- ⚠️ Suicidal Ideation and Behavior: FDA prescribing information instructs monitoring for emergence or worsening of depression, suicidal thoughts, or unusual mood changes; patients should report any such symptoms promptly.
- ⚠️ Heart Rate Increase: Mean increases in resting heart rate of approximately 2–4 beats per minute were observed in SURMOUNT clinical trials; FDA labeling advises monitoring in patients with known cardiac conditions.
Managing Side Effects
Nausea
According to SURMOUNT-1 trial data, nausea was most prevalent during dose escalation steps and generally decreased over time. Practical strategies include eating smaller portions, choosing low-fat and low-odor foods, eating slowly and stopping when satiated, avoiding lying down immediately after eating, and staying well hydrated. Ginger-containing products have anecdotal support but are not endorsed in FDA labeling. If nausea is severe or persistent, the prescribing information supports temporarily delaying a dose escalation step.
Vomiting
Vomiting was reported most frequently in the first weeks of treatment in SURMOUNT clinical trials. Adequate hydration is critical to prevent dehydration and secondary kidney injury noted in FDA labeling. Patients should contact their prescriber if vomiting prevents oral fluid intake or lasts more than 24 hours. FDA labeling supports dose escalation delays if GI tolerability is poor.
Constipation
Constipation results from tirzepatide's mechanism of slowing gastric and intestinal motility, as described in FDA prescribing information. Increasing dietary fiber (fruits, vegetables, whole grains) and fluid intake are standard approaches. Physical activity may support bowel regularity. Patients should discuss the use of fiber supplements or osmotic laxatives with their prescriber; FDA labeling does not specifically endorse particular OTC products.
Diarrhea
Diarrhea was reported in approximately 23% of patients receiving 15 mg tirzepatide in SURMOUNT-1. Maintaining hydration is the primary concern. Patients should avoid high-fat and high-sugar foods that may worsen loose stools. If diarrhea is persistent or accompanied by signs of dehydration (dizziness, dark urine), medical attention is warranted per FDA labeling guidance on acute kidney injury.
Injection-Site Reactions
FDA prescribing information recommends rotating injection sites with each weekly dose among the abdomen, thigh, or upper arm. Avoid injecting into areas that are tender, bruised, red, or hardened. Allowing the pen to reach room temperature before injecting may reduce discomfort.
Hair Thinning
Alopecia was reported as an adverse event in SURMOUNT-1. Based on the pattern observed in clinical trials, hair thinning appears to be consistent with telogen effluvium — a temporary shedding triggered by rapid caloric restriction and weight loss rather than a direct toxic drug effect. Ensuring adequate protein intake is frequently discussed in clinical settings; patients experiencing significant hair loss should notify their prescriber to rule out other causes.
Hypoglycemia
FDA labeling specifically warns that patients taking Zepbound concurrently with insulin or sulfonylureas face increased hypoglycemia risk. Patients should know the symptoms of low blood sugar (shakiness, sweating, confusion, rapid heartbeat) and have a plan for treatment. Dose adjustments of the concurrent diabetes medications may be required; this must be managed by a prescriber.
Cost and Access in 2026
Cash Price (Without Insurance)
Zepbound's list price as set by Eli Lilly is approximately $1,059.87 per month (four single-dose autoinjector pens) across all doses, as established at launch and subject to periodic adjustment. Actual pharmacy cash prices may vary. Patients should verify current pricing directly with their pharmacy or through Eli Lilly's official channels, as prices change over time.
Eli Lilly Savings Program
Eli Lilly offers the Zepbound Savings Card for eligible commercially insured patients, which may reduce out-of-pocket costs to as low as $25 per month (subject to program terms, eligibility requirements, and caps). Lilly also launched single-dose vials through its LillyDirect self-pay program at lower list prices than the autoinjector pens. Eligibility, pricing, and program terms are subject to change; verify at zepbound.com or by calling Lilly directly.
Insurance Coverage
Coverage for Zepbound varies significantly by insurance plan and employer. As of 2026, many commercial plans cover Zepbound for obesity with prior authorization requirements. Medicare Part D coverage for anti-obesity medications has expanded following the Treat and Reduce Obesity Act provisions; however, coverage specifics depend on individual plan formularies. Medicaid coverage varies by state. Patients should contact their insurer directly to confirm current formulary status and prior authorization criteria.
Patient Assistance
The Lilly Cares Foundation Patient Assistance Program may provide Zepbound at no cost for qualifying uninsured or underinsured patients who meet income eligibility requirements. Patients can apply through LillyAnswers at 1-800-545-5979 or at lillycares.com. Program terms, income thresholds, and availability are subject to change.
Frequently Asked Questions
How much weight can I expect to lose on Zepbound?
According to SURMOUNT-1 trial data published in the New England Journal of Medicine (2022), participants receiving tirzepatide 15 mg achieved a mean weight reduction of approximately 20.9% of body weight over 72 weeks, compared to 3.1% with placebo. Individual results vary based on dose, adherence, diet, and physical activity. These figures come from clinical trial participants and are not guarantees of individual outcomes.
What happens if I stop taking Zepbound?
The SURMOUNT-4 trial (published in JAMA, 2024) found that participants who discontinued tirzepatide after 36 weeks of treatment and switched to placebo regained approximately two-thirds of their prior weight loss over the following 52 weeks, while those who continued tirzepatide maintained their weight loss. This suggests that the weight management effects of Zepbound are dependent on continued use, consistent with its classification as a chronic weight management medication.
What are Zepbound's available doses?
Per the FDA-approved prescribing information, Zepbound is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all as once-weekly subcutaneous injections. The recommended starting dose is 2.5 mg once weekly for four weeks, followed by dose escalation in 2.5 mg increments at four-week intervals as tolerated. The maximum approved dose is 15 mg once weekly.
Where can Zepbound be injected?
According to FDA prescribing information, Zepbound should be injected subcutaneously (under the skin) in the abdomen, thigh, or upper arm. Patients should rotate injection sites each week. Zepbound should not be injected into a vein or muscle. The medication should not be injected into areas of skin that are damaged, tender, bruised, or scarred.
Is Zepbound safe during pregnancy?
FDA prescribing information states that Zepbound is not recommended during pregnancy. Animal reproduction studies showed adverse effects on fetal development. Weight loss during pregnancy is not recommended and may cause fetal harm. Women who are pregnant or planning to become pregnant should notify their prescriber. The FDA label advises discontinuing Zepbound at least 2 months before a planned pregnancy due to the drug's long washout time.
Can Zepbound be used in patients with type 2 diabetes?
The SURMOUNT-2 trial (published in The Lancet, 2023) specifically evaluated tirzepatide in adults with obesity and type 2 diabetes. Participants receiving tirzepatide 15 mg achieved a mean weight reduction of approximately 14.7% over 72 weeks. The FDA label for Zepbound notes that it can be used in patients with type 2 diabetes but clarifies that Mounjaro (tirzepatide) is the FDA-approved agent for type 2 diabetes glycemic control specifically. Prescribers manage the choice of agent for patients with both conditions.
How should Zepbound be stored?
Per FDA prescribing information, Zepbound pens should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). They may be stored at room temperature (up to 86°F / 30°C) for up to 21 days. Zepbound should be protected from light and should not be frozen; pens that have been frozen must be discarded. The pen should be inspected before each use — the solution should appear clear to slightly opalescent; do not use if it appears cloudy, discolored, or contains visible particles.
What drugs interact with Zepbound?
FDA prescribing information identifies oral medications as a key interaction concern: because tirzepatide slows gastric emptying, it may affect the absorption rate of orally administered drugs. Patients taking oral contraceptives are advised to use a non-oral backup contraceptive method or use an oral contraceptive with at least 4 weeks before and after starting each dose escalation. Patients taking warfarin or other narrow-therapeutic-index drugs should be monitored closely and should notify all their prescribers that they are taking Zepbound.